tbuckley/cabot-search huggingface dataset:
Abstract PS11-01: Outcome without adjuvant systemic treatment in breast cancer patients included in the MINDACT trial
Authors: Josephine MN Lopes Cardozo, Danalyn Byng, Caroline A Drukker, Marjanka K Schmidt, Laura J van 't Veer, Fatima Cardoso, Martine Piccart, Coralie Poncet, Emiel JTh Rutgers
Journal: Cancer Research (2021)

Abstract Background: Adjuvant systemic treatments have played an important role in the decline of breast cancer mortality over the years. Because of the extensive short- and long-term toxicities associated with these treatments, careful selection of patients likely to benefit from them is needed. Studies have shown excellent survival in subgroups of patients receiving no adjuvant systemic treatments. Some national guidelines advise no adjuvant systemic treatments in specific groups of patients with clinical low risk breast cancer. The aim of this study is to investigate the survival of breast cancer patients who received no adjuvant treatment (chemotherapy nor endocrine therapy) using data from the EORTC 10041/BIG 3-04 MINDACT trial. Material and methods: Of the 6693 patients enrolled in the MINDACT trial, accrued 2007-2011, 509 patients with hormone receptor positive, HER2 negative, lymph node negative tumors &amp;lt;2cm received no adjuvant systemic treatment, mostly following local recommendations. Median follow-up was 8.7 years. Using propensity score matching and exact matching, we will identify groups of patients treated with adjuvant endocrine therapy and/or chemotherapy with similar tumor characteristics to the untreated patients. We will use the Kaplan-Meier method to estimate distant metastasis free interval and overall survival at 5 and 8 years for each group. Differences between groups will be evaluated using the log-rank test, and hazard ratios with 95% CI derived from Cox proportional hazards models. Planned analyses: The long-term data of the MINDACT trial has recently become available. The date of planned analysis is August 10th 2020.For this study, the primary clinical endpoint will be distant metastasis free interval, which will be assessed in the matched groups of untreated patients, patients who received endocrine therapy only, and patients who received chemotherapy with or without endocrine therapy. Kaplan-Meier estimates will be provided at 5 years, and at 8 years to assess the long-term outcomes in this population. A statistical plan for this analysis was specifically developed and approved prior to performing any analysis. Citation Format: Josephine MN Lopes Cardozo, Danalyn Byng, Caroline A Drukker, Marjanka K Schmidt, Laura J van 't Veer, Fatima Cardoso, Martine Piccart, Coralie Poncet, Emiel JTh Rutgers. Outcome without adjuvant systemic treatment in breast cancer patients included in the MINDACT trial [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS11-01.
The Ghost-Patient Panel
Authors: Adam S. Cifu
Journal: Annals of Internal Medicine (2021)

On Being a DoctorFebruary 2021The Ghost-Patient PanelAdam S. Cifu, MDAdam S. Cifu, MDThe University of Chicago Chicago, IllinoisSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M20-4618 Audio Reading - “The Ghost-Patient Panel” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads “The Ghost-Patient Panel” by Adam S. Cifu, MD Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Like all clinicians, I have many patient panels. Some panels are generated by the EHR system. Others are personal, ones I curate myself.My patient panel that is most accessible, available in the EHR, is the one I almost never access. This is the list of “My Patients.” All the patients considered by the EHR to belong to me.I have other patient panels not found in the EHR. These are the ones that I create and revise. One of these panels is maintained as the “face sheet” of every outpatient I have ever cared for who died. The latest ... Author, Article, and Disclosure InformationAffiliations: The University of Chicago Chicago, IllinoisCorresponding Author: Adam S. Cifu, MD, 5841 South Maryland Avenue, MC 3051, Chicago, IL 60637; e-mail, [email protected]edu. PreviousarticleNextarticle Advertisement Audio Reading - “The Ghost-Patient Panel” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads “The Ghost-Patient Panel” by Adam S. Cifu, MD Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics February 2021Volume 174, Issue 2Page: 270KeywordsConsciousnessHealth careHealth insuranceInterleukinsMedicareNerve fibersOutpatientsPancreatic cancerPatient advocacySurgeons ePublished: 16 February 2021 Issue Published: February 2021 Copyright & PermissionsCopyright © 2021 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis
Authors: Sarah F Ackley, Scott C Zimmerman, Willa D Brenowitz, Eric J Tchetgen Tchetgen, Audra L Gold, Jennifer J Manly, Elizabeth Rose Mayeda, Teresa J Filshtein, Melinda C Power, Fanny M Elahi, Adam M Brickman, M Maria Glymour
Journal: BMJ (2021)

<h3>Abstract</h3> <h3>Objective</h3> To evaluate trials of drugs that target amyloid to determine whether reductions in amyloid levels are likely to improve cognition. <h3>Design</h3> Instrumental variable meta-analysis. <h3>Setting</h3> 14 randomized controlled trials of drugs for the prevention or treatment of Alzheimer’s disease that targeted an amyloid mechanism, identified from ClinicalTrials.gov. <h3>Population</h3> Adults enrolled in randomized controlled trials of amyloid targeting drugs. Inclusion criteria for trials vary, but typically include adults aged 50 years or older with a diagnosis of mild cognitive impairment or Alzheimer’s disease, and amyloid positivity at baseline. <h3>Main outcome measures</h3> Analyses included trials for which information could be obtained on both change in brain amyloid levels measured with amyloid positron emission tomography and change in at least one cognitive test score reported for each randomization arm. <h3>Results</h3> Pooled results from the 14 randomized controlled trials were more precise than estimates from any single trial. The pooled estimate for the effect of reducing amyloid levels by 0.1 standardized uptake value ratio units was an improvement in the mini-mental state examination score of 0.03 (95% confidence interval −0.06 to 0.1) points. This study provides a web application that allows for the re-estimation of the results when new data become available and illustrates the magnitude of the new evidence that would be necessary to achieve a pooled estimate supporting the benefit of reducing amyloid levels. <h3>Conclusions</h3> Pooled evidence from available trials reporting both reduction in amyloid levels and change in cognition suggests that amyloid reduction strategies do not substantially improve cognition.
A Blueprint for Comprehensive Medicaid Reform
Authors: Rebekah E. Gee, David Shulkin, Iyah Romm
Journal: JAMA (2021)

This Viewpoint proposes broad principles to guide Medicaid reform as a means to advance health equity, including stabilization of its funding and coverage; coordination of its infrastructure; alignment of health care and social spending at the point of care; and a value-based approach to benefits.
低接着性足場コラーゲン(LASCOL)による自発的回転楕円体形成を介した減少した核切開により誘発された椎間板破壊【JST・京大機械翻訳】
Authors: Takeoka Yoshiki, Yurube Takashi, Morimoto Koichi, Kunii Saori, Kanda Yutaro, Tsujimoto Ryu, Kawakami Yohei, Fukase Naomasa, Takemori Toshiyuki, Omae Kaoru, Kakiuchi Yuji, Miyazaki Shingo, Kakutani Kenichiro, Takada Toru, Nishida Kotaro, Fukushima Masanori, Kuroda Ryosuke
Journal: Biomaterials (2020)
redPATH: Reconstructing the Pseudo Development Time of Cell Lineages in Single-Cell RNA-Seq Data and Applications in Cancer
Authors: Kaikun Xie, Zehua Liu, Ning Chen, Ting Chen
Journal: Genomics Proteomics & Bioinformatics (2021)

Abstract The recent advancement of single-cell RNA sequencing (scRNA-seq) technologies facilitates the study of cell lineages in developmental processes and cancer. In this study, we developed a computational method, called redPATH, to reconstruct the pseudo developmental time of cell lineages using a consensus asymmetric Hamiltonian path algorithm. Besides, we developed a novel approach to visualize the trajectory development and implemented visualization methods to provide biological insights. We validated the performance of redPATH by segmenting different stages of cell development on multiple neural stem cell and cancer datasets, as well as other single-cell transcriptome data. In particular, we identified a stem cell-like subpopulation in malignant glioma cells. These cells express known proliferative markers, such as GFAP, ATP1A2, IGFBPL1, and ALDOC, and remain silenced for quiescent markers such as ID3. Furthermore, we identified MCL1 as a significant gene that regulates cell apoptosis and CSF1R for reprogramming macrophages to control tumor growth. In conclusion, redPATH is a comprehensive tool for analyzing scRNA-seq datasets along the pseudo developmental time. redPATH is available at https://github.com/tinglabs/redPATH.
Abstract PS10-58: Cost effectiveness of routine cardiac imaging during adjuvant trastuzumab in HER2-positive breast cancer
Authors: Vineeth Tatineni, Daniel Redle, Daljeet Singh, Arifa Abid, Sameer Mahesh
Journal: Cancer Research (2021)

Abstract Background: Guidelines recommend patients treated with trastuzumab (TRA) undergo a multiple gated-acquisition (MUGA) scan or echocardiogram (ECHO) at baseline and every 3 months thereafter. In this retrospective study, we evaluated the incidence of clinically significant cardiotoxicity and analyzed cost effectiveness of routine cardiac imaging during adjuvant TRA. Methods: HER2-positive breast cancer patients treated with adjuvant TRA between 2015 and 2019 were investigated. Information regarding comorbidities, clinical diagnosis of cardiotoxicity, and alterations in therapy were collected. ECHO and MUGA scans were reviewed to monitor trends in ejection fractions (EF). Data was analyzed via the FREQ procedure. We defined clinically significant cardiotoxicity as holding or discontinuing TRA regimen. Results: We found 108 patients. Median age was 57 years (interquartile range (IQR) of 47-68 years); 86% Caucasian and 12% African American. 3% had preexisting heart failure, 43% hypertension, 14% diabetes, 4% coronary artery diseases, 32% hyperlipidemia, 2% chronic kidney disease, 6% stroke, and 38% were smokers. No patients received anthracycline containing regimens. 30 patients (27.7%) had EF drop &amp;gt;10% from baseline. Six patients (5.5%) were identified with clinically significant cardiotoxicity; 4 (3.7%) had EF &amp;lt; 50% and 3 of those 4 were symptomatic (2.7% of total). Median time from initiation to decline in EF &amp;gt; 10% was 6 months (IQR of 4.5-7.5 months). Conclusions: Current practice for TRA cardiotoxicity monitoring consists of cardiac imaging every 3 months. The average cost for a MUGA scan and ECHO is approximately $3700 and $2500, respectively. We determined that clinically significant cardiotoxicity, occurred in 5.5% of the patients approximately 6 months into treatment. With TRA causing reversible cardiotoxicity and 2.7% of the patients being symptomatic, cardiac imaging every 3 months appears excessive, especially in patients without comorbidities. Baseline cardiac imaging with repeat assessment in 6 months appears sufficient in non-anthracycline containing regimen. This strategy allows cost savings of approximately $6000 per patient. Characteristics of patients with clinical cardiotoxicityClinically Significant Cardiotoxicity (N=6)StageChemotherapy RegimenHeart Failure SymptomsEF drop below 50%Initiation to Drop in EF &amp;gt;10% (months)Discontinuation to Recovery in EF (months)1IIBTCHPNoNo3.21.12IATCHPYesYes6.12.83IIATCHNoNo9.31.34IBTCHYesYes6.54.85IIATHYesYes6.12.66IIATCHPNoYes6.31.2 Citation Format: Vineeth Tatineni, Daniel Redle, Daljeet Singh, Arifa Abid, Sameer Mahesh. Cost effectiveness of routine cardiac imaging during adjuvant trastuzumab in HER2-positive breast cancer [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS10-58.
Fusion 68Ga-DOTANOC PET/MRI in Primary Juvenile Nasal Angiofibroma
Authors: Pirabu Sakthivel, Alok Thakar, Sreedharan Thankarajan Arunraj, Ashu Seith Bhalla, Arun Prashanth, Rakesh Kumar
Journal: Clinical Nuclear Medicine (2021)

Somatostatin cell surface receptors are expressed in many different benign and malignant tumors and are often exploited for imaging and therapy of neuroendocrine tumors. A 17-year-old adolescent boy with clinicoradiologically diagnosed JNA (juvenile nasopharyngeal angiofibroma) also underwent 68Ga-DOTANOC PET to explore somatostatin cell surface receptors' expression and its theranostic potential. Fusion PET/MRI, a novel imaging technology, exactly depicted the anatomical extensions of the tumor with avid DOTANOC uptake. This software-based fusion technique is advantageous for easy early recurrence identification, better delineation from postoperative scar tissue, for planning the exact target volumes for stereotactic radiotherapy therapy of inoperable/residual/recurrent JNAs in the future.
A unique bipartite Polycomb signature regulates stimulus-response transcription during development
Authors: Taro Kitazawa, Dania Machlab, Onkar Joshi, Nicola Maiorano, Hubertus Kohler, Sebastien Ducret, Sandra Kessler, Henrik Gezelius, Charlotte Soneson, Panagiotis Papasaikas, Guillermina López-Bendito, Michael B. Stadler, Filippo M. Rijli
Journal: Nature Genetics (2021)
Reply to Brett Delahunt, Hemamali Samaratunga, Lars Egevad’s Letter to the Editor re: Svetlana Avulova, John C. Cheville, Christine M. Lohse, et al. Grading of Chromophobe Renal Cell Carcinoma: Evidence for a Four-tiered Classification Incorporating Coagulative Tumor Necrosis. Eur Urol 2021;79:225–31. Should Chromophobe Renal Cell Carcinoma Be Graded?
Authors: Svetlana Avulova, John C. Cheville, Christine M. Lohse, Aaron M. Potretzke
Journal: European Urology (2021)
Trends in Use of Telehealth Among Health Centers During the COVID-19 Pandemic — United States, June 26–November 6, 2020
Authors: Hanna B. Demeke, Sharifa Merali, Suzanne Marks, Leah Zilversmit Pao, Lisa Romero, Paramjit Sandhu, Hollie Clark, Alexey Clara, Kendra B. McDow, Erica Tindall, Stephanie Campbell, Joshua Bolton, Xuan Le, Julia L. Skapik, Isaac Nwaise, Michelle A. Rose, Frank V. Strona, Christina Nelson, Charlene Siza
Journal: MMWR Morbidity and Mortality Weekly Report (2021)

Telehealth can facilitate access to care, reduce risk for transmission of SARS-CoV-2 (the virus that causes coronavirus disease 2019 ), conserve scarce medical supplies, and reduce strain on health care capacity and facilities while supporting continuity of care.Health Resources and Services Administration (HRSA)-funded health centers* expanded telehealth † services during the COVID-19 pandemic (1).The Centers for Medicare & Medicaid Services eliminated geographic restrictions and enhanced reimbursement so that telehealth services-enabled health centers could expand telehealth services and continue providing care during the pandemic (2,3).CDC and HRSA analyzed data from 245 health centers that completed a voluntary weekly HRSA Health Center COVID-19 Survey § for 20 consecutive weeks to describe trends in telehealth use.During the weeks ending June 26-November 6, 2020, the overall percentage of weekly health care visits conducted via telehealth (telehealth visits) decreased by 25%, from 35.8% during the week ending June 26 to 26.9% for the week ending November 6, averaging 30.2% over the study period.Weekly telehealth visits declined when COVID-19 cases were decreasing and plateaued as cases were increasing.Health centers in the South and in rural areas consistently reported the lowest average percentage of weekly telehealth visits over the 20 weeks, compared with health centers in other regions and urban areas.As the COVID-19 pandemic continues, maintaining and expanding telehealth services will be critical to ensuring access to care while limiting exposure to SARS-CoV-2.In April 2020, HRSA began administering a voluntary weekly Health Center COVID-19 Survey to track the effect of COVID-19 on health centers' testing capacity, operations, patients, and staff members.Potential respondents were 1,382 HRSA-funded health centers.CDC and HRSA analyzed data from 245 health centers that responded to the Health Center COVID-19 Survey for 20 consecutive weeks (weeks ending * Data from HRSA-funded health centers (i.e., Federally Qualified Health Centers) are included for the analysis presented.† Telehealth consists of the use of electronic information and telecommunication technologies to support clinical health care, patient and professional healthrelated education, public health, and health administration.https://www.hrsa.gov/rural-health/telehealth § https://bphc.hrsa.
Abstract PS19-14: Matrin3 inhibits breast cancer growth by suppressing microtubule nucleation protein MZT2B
Authors: Panneerdoss Subbarayalu, Subapriya Rajamanickam, Suryavathi Viswanadhapalli, Fuyang Li, Vijay Eedunuri, Pooja Yadav, Esha Reddy, Santosh Timilsina, Saif SR Nirzhor, Benjamin C Onyeagucha, Li-Ju Wang, Yu-Chiao Chiu, Tabrez Mohammad, Nourhan Abdelfattah, Nicholas Dybdal-Hargreaves, Yidong Chen, Ratna Vadlamudi, Manjeet Rao
Journal: Cancer Research (2021)

Abstract Despite improvement in overall survival, many patients with breast cancers still succumb to this disease. Identification of new biomarkers and safe therapeutic targets are urgently needed to improve the overall clinical outcome of breast cancer patients. Our studies discovered a RNA binding protein, MATRIN3 (MATR3), as a novel tumor suppressor. MATR3 is expressed at a significantly reduced levels in breast tumors. MATR3 inhibited short and long-term viability as well as migration and invasion of breast cancer cells. Further, MATR3 overexpression suppressed tumor growth, while its depletion induced tumor growth in orthotopic mouse tumor models. RNA seq and RNA immunoprecipitation analyses revealed that MATR3 binds and directly regulates the expression of several microtubule-associated proteins. Mechanistic studies identified MZT2B, a mitotic spindle organizing protein as a down stream effector of MATR3. MZT2B knockdown or knockout using CRISPR-CAS9 resulted in significantly decreased short and long term viability as well as reduced migration and invasion of breast cancer cells. Notably, MZT2B overexpression rescued the inhibitory effect of MATR3 overexpression on breast cancer growth. Furthermore, MATR3 overexpression downregulated expression of key microtubule nucleation protein complex including γ-tubulin and γ-tubulin ring complex protein (TUBGCP). Our data suggest that MATR3 inhibits breast cancer growth and progression by inhibiting MZT2B and consequently microtubule nucleation in breast cancers. Citation Format: Panneerdoss Subbarayalu, Subapriya Rajamanickam, Suryavathi Viswanadhapalli, Fuyang Li, Vijay Eedunuri, Pooja Yadav, Esha Reddy, Santosh Timilsina, Saif SR Nirzhor, Benjamin C Onyeagucha, Li-Ju Wang, Yu-Chiao Chiu, Tabrez Mohammad, Nourhan Abdelfattah, Nicholas Dybdal-Hargreaves, Yidong Chen, Ratna Vadlamudi, Manjeet Rao. Matrin3 inhibits breast cancer growth by suppressing microtubule nucleation protein MZT2B [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS19-14.
DUSP22 Rearrangements Identify a Molecularly Distinct Type of Anaplastic Large Cell Lymphoma Characterized By DNA Hypomethylation and Lack of Activated STAT3
Authors: Rebecca Boddicker, Surendra Dasari, Naoki Oishi, Guangzhen Hu, Jagmohan Sidhu, Julie Cunningham, Zhifu Sun, Saurabh Baheti, Julie C Porcher, Stephen M Ansell, Nabila Nora Bennani, James R. Cerhan, Andrew L Feldman
Journal: Blood (2017)
춘계학술대회 : 구연 ; 담관세포에서 Raf-1 활성을 통한 Lysophosphatidylcholine의 cyclooxygenase-2 발현 유도 및 항자멸사 효과
Authors: 윤정환, 곽금연, 김윤준, 이효석, 김정룡
Journal: Clinical and Molecular Hepatology (2005)

배경/목적: 최근 담관세포암의 진단 및 치료에 관한 많은 연구와 발전이 이루어져 왔지만 아직 그 예후는 불량하며 수술 이외의 효과적인 근치적 치료법은 없는 상황으로, 효과적인 치료약제 개발을 위한 담관세포암의 발생 및 진행과 관련된 원인적 기전 규명이 필수적이다. 한편, 담관세포암의 선행 질환으로는 췌담도 합류 이상이 잘 알려져 있으며 췌담도 합류 이상의 구조적 이상에 동반되는 담즙의 구성 성분 변화가 그 원인적 인자로 거론되고 있으나 구체적인 기전은
Roger Allum Hobdell
Authors: Eliot Hobdell, Nolan Hobdell, Benjamin Hobdell, Michael Hobdell, Marion Bray, Elizabeth Urban
Journal: BMJ (2021)

Roger Allum Hobdell grew up in north London and with his twin brother attended Mill Hill School. He then enrolled at the London Hospital, where he studied medicine; his twin, Martin, became an academic dentist. During their training the twins represented their school, college, and university on the track and in the gym and diving pool. After qualifying and doing house jobs in London and Cornwall, Roger embarked on psychiatric training in London’s East End and later at …
The MafA-target gene PPP1R1A regulates GLP1R-mediated amplification of glucose-stimulated insulin secretion in β-cells
Authors: Luis Rodrigo Cataldo, Neelanjan Vishnu, Tania Singh, Ludivine Bertonnier-Brouty, Sara Bsharat, Cheng Luan, Erik Renström, Rashmi B. Prasad, Malin Fex, Hindrik Mulder, Isabella Artner
Journal: Metabolism (2021)

The amplification of glucose-stimulated insulin secretion (GSIS) through incretin signaling is critical for maintaining physiological glucose levels. Incretins, like glucagon-like peptide 1 (GLP1), are a target of type 2 diabetes drugs aiming to enhance insulin secretion.Here we show that the protein phosphatase 1 inhibitor protein 1A (PPP1R1A), is expressed in β-cells and that its expression is reduced in dysfunctional β-cells lacking MafA and upon acute MafA knock down. MafA is a central regulator of GSIS and β-cell function. We observed a strong correlation of MAFA and PPP1R1A mRNA levels in human islets, moreover, PPP1R1A mRNA levels were reduced in type 2 diabetic islets and positively correlated with GLP1-mediated GSIS amplification. PPP1R1A silencing in INS1 (832/13) β-cells impaired GSIS amplification, PKA-target protein phosphorylation, mitochondrial coupling efficiency and also the expression of critical β-cell marker genes like MafA, Pdx1, NeuroD1 and Pax6. Our results demonstrate that the β-cell transcription factor MafA is required for PPP1R1A expression and that reduced β-cell PPP1R1A levels impaired β-cell function and contributed to β-cell dedifferentiation during type 2 diabetes. Loss of PPP1R1A in type 2 diabetic β-cells may explains the unresponsiveness of type 2 diabetic patients to GLP1R-based treatments.